Correction of information in the magazine Affärsvärlden


The correct facts are the following:
Sven Andréasson last week increased his holding of 38,250 shares with additionally 1,750 shares and now holds a total of 40,000 shares, 175,000 call options and 11,200 personnel stock options.
Lund, August 25, 2004
Active Biotech AB (publ)
Sven Andréasson
President & CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/ inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases, as well as a novel concept for use in cancer immunotherapy.
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50